INM — InMed Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1728328 ·
British Columbia, Canada
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -2,010,808 | -2,330,778 | 1,305,862 | 1,094,488 | 2,505,258 |
| Jun 2026 | 0 | — | -3,211,149 | -5,839,392 | 3,030,067 | 2,194,413 | 1,955,060 |
| Mar 2026 | 0 | — | -2,816,353 | -2,966,336 | 9,133,806 | 5,158,932 | 2,242,032 |
| Dec 2025 | 820,188 | 184,194 | -2,120,738 | -2,028,223 | 11,191,484 | 6,954,834 | 1,603,820 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,459,785
Investing CF
$2,417
Financing CF
$271,674
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-21.00
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-132,561,184
Inventory
$947,898
Receivables
$182,967
ST Investments
—
EBIT TTM
$-11,663,144
Pretax Income TTM
$-11,658,048
Interest Exp TTM
$30,700
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,942,633
EBITDA
$-9,886,568
Free Cash Flow
$-2,728,912
Enterprise Value
$84,347,696
Total Cash
$1,134,819
Total Debt
$0
Shares Out
549,374
Trailing EPS
$-27.60
Book Value
$-0.22
ROE
-222.1%
ROA
-85.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | -9,895,116 | -12,560,850 | 3,030,067 | 1,955,060 | 1,075,007 | -8,643,513 |
| Jun 2025 | 0 | -8,446,170 | -8,162,133 | 15,580,040 | 2,145,545 | 13,434,495 | -8,099,392 |
| Jun 2024 | 4,597,730 | -8,134,430 | -7,675,550 | 11,822,782 | 2,616,673 | 9,206,109 | -6,985,832 |
| Jun 2023 | 4,135,561 | -8,378,787 | -7,947,622 | 14,106,340 | 2,016,613 | 12,089,727 | -7,283,199 |
| Jun 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$244,971
NetIncome TTM
$-12,560,850
OpCashFlow TTM
—
Assets (Latest)
$9,133,806
Forward EPS
$-6.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing
2026-11-09 12:00 · Yahoo
Fox-Roku’s $22B Deal, A New Nasdaq Biotech And A $25B Chemicals Tie-Up: Deals Investors Are Watching
2026-11-09 06:16 · Yahoo
InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics
2026-11-06 21:05 · Yahoo
InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"
2026-11-05 21:01 · Yahoo
InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation
2026-11-04 21:51 · Yahoo
InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update
2026-11-03 12:30 · Yahoo
InMed Announces Share Consolidation in Connection with Proposed Merger
2026-11-02 21:15 · Yahoo
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM)
2026-05-19 14:37 · Yahoo
/C O R R E C T I O N -- InMed Pharmaceuticals/
2026-05-19 18:21 · Yahoo
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
2026-06-04 21:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.